Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
01/12/2017 01/13/2017 01/17/2017 01/18/2017 01/19/2017 Date
0.4052(c) 0.43(c) 0.46(c) 0.485(c) 0.509(c) Last
584 998 1 329 836 1 623 684 3 026 355 3 513 706 Volume
+0.05% +6.12% +6.98% +5.43% +4.95% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 3,23x
Capi. / Sales2014 1,42x
Capitalization 50,9 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
01/09 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Results of Operations a..
01/09 PROTALIX BIOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, ..
01/09 Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 20..
01/05 PROTALIX BIOTHERAPEUTICS : Announces Positive Interim Results from Phase II Clin..
01/05 PROTALIX BIOTHERAPEUTICS : Receives Confirmation of Order for over $24 Million o..
01/05 PROTALIX BIOTHERAPEUTICS : Announces Last Patient Enrolled in the AIR DNase&trad..
01/05 PROTALIX BIOTHERAPEUTICS : Receives Letter Detailing Intended Purchases of Appro..
01/03 PROTALIX BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
01/03 Protalix BioTherapeutics Announces Positive Interim Results from Phase II Cli..
2016 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Other Events
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 1 180%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTI..8.99%51
INCYTE CORPORATION17.21%22 141
QUINTILES IMS HOLDINGS..0.03%18 727
CELLTRION, INC.--.--%10 532
LONZA GROUP AG4.14%9 648
ALKERMES PLC0.90%8 523
More Results